12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $41M | -$160M | 0.0% | -394.9% | -586.6% | -85.8% | -$166M | $59M | $147M |
| 2024 | $32M | -$237M | 0.0% | -777.2% | -176.6% | -69.4% | -$219M | $57M | $132M |
| 2023 | $78M | -$153M | 0.0% | -216.6% | -43.9% | -30.7% | -$137M | $0 | $124M |
| 2022 | $20M | -$220M | 0.0% | -1146.3% | -61.1% | -42.9% | -$181M | — | $142M |
| 2021 | $26M | -$193M | 0.0% | -756.1% | -34.8% | -28.4% | -$172M | — | $204M |
| 2020 | $91M | -$116M | 0.0% | -148.6% | -29.5% | -20.3% | -$187M | — | $140M |
| 2019 | $21M | -$134M | 0.0% | -686.4% | -51.0% | -26.3% | -$47M | — | $238M |
| 2018 | $32M | -$110M | 0.0% | -356.1% | -46.6% | -26.2% | -$50M | — | $135M |
| 2017 | $14M | -$120M | 0.0% | -873.6% | -57.8% | -32.2% | -$11M | — | $147M |
| 2016 | — | -$97M | — | — | -72.2% | -42.4% | -$54M | — | $185M |
| 2015 | — | -$73M | — | — | 87.7% | -48.8% | -$7M | — | $143M |
| 2014 | — | -$14M | — | — | 89.5% | — | — | — | $11M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $12M | -$18M | 0.0% | -156.0% | -17.3% | -7.7% | -$30M | $56M | $182M |
| Mar '26 | $3M | -$25M | 0.0% | -883.2% | -566.7% | -16.7% | -$23M | $55M | $124M |
| Dec '25 | $25M | -$6M | 0.0% | -31.3% | -20.6% | -3.0% | -$36M | $59M | $147M |
| Sep '25 | $8M | -$25M | 0.0% | -325.4% | -186.7% | -12.4% | -$31M | $59M | $166M |
| Jun '25 | $4M | -$53M | 0.0% | -1440.6% | -277.4% | -25.3% | -$50M | $57M | $139M |
| Mar '25 | $5M | -$76M | 0.0% | -1635.1% | -121.9% | -28.9% | -$48M | $55M | $139M |
| Dec '24 | $31M | -$45M | 0.0% | -152.2% | -33.8% | -13.3% | -$51M | $57M | $132M |
| Sep '24 | $61000 | -$62M | 0.0% | -107649.2% | -35.4% | -19.0% | -$56M | — | $96M |
| Jun '24 | $513000 | -$68M | 0.0% | -14016.2% | -29.1% | -17.6% | -$61M | — | $64M |
| Mar '24 | $1M | -$62M | 0.0% | -5902.3% | -21.0% | -14.1% | -$52M | — | $69M |
| Dec '23 | $60M | -$19M | 0.0% | -39.9% | -5.4% | -3.8% | -$24M | $0 | $124M |
| Sep '23 | $5M | -$45M | 0.0% | -940.1% | -12.5% | -8.9% | -$36M | — | $83M |
| Jun '23 | $3M | -$40M | 0.0% | -1527.3% | -10.1% | -7.4% | -$40M | — | $221M |
| Mar '23 | $10M | -$49M | 0.0% | -517.3% | -15.4% | -10.6% | -$38M | — | $129M |
| Dec '22 | $7M | -$61M | 0.0% | -970.7% | -16.8% | -11.8% | -$43M | — | $142M |
| Sep '22 | $42000 | -$56M | 0.0% | -136952.4% | -13.4% | -10.5% | -$49M | — | $211M |
| Jun '22 | $6M | -$53M | 0.0% | -852.5% | -11.5% | -9.2% | -$38M | — | $169M |
| Mar '22 | $7M | -$51M | 0.0% | -749.5% | -9.9% | -8.1% | -$51M | — | $211M |
| Dec '21 | $12M | -$41M | 0.0% | -333.7% | -7.5% | -6.1% | -$37M | — | $204M |
| Sep '21 | $6M | -$39M | 0.0% | -633.4% | -6.7% | -5.5% | -$43M | — | $260M |
How the market has priced EDIT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Editas Medicine, Inc.'s revenue has declined 14.9% per year. These are computed facts, not advice.
As of FY2025, Editas Medicine, Inc. reported $59M of total debt against $147M of cash; operating income covered interest expense -75.2×.
In FY2025, gross margin was —, operating margin -394.9%, and net margin -395.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.